Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.
波士顿，2024年11月27日（环球新闻社）--inozyme pharma公司（纳斯达克：INZY）（“该公司”或“Inozyme”），一家临床阶段的生物制药公司，在骨骼健康和血管功能受影响的罕见疾病领域开发创新治疗药物，今天宣布，Inozyme的首席运营官兼高级副总裁Matt Winton博士将于2024年12月4日星期三美国东部时间下午2:30-2:55在派杰投资第36届医疗保健年会上进行一场炉边聊天。
A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme's website under events, where a replay of the event will also be available for a limited time.
可以在Inozyme网站的投资者关系活动中访问座谈会的实时网络广播，活动的重播也将在有限时间内提供。
About Inozyme Pharma
关于Inozyme Pharma
Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).
inozyme pharma是一家开拓性的临床阶段生物制药公司，致力于开发创新的治疗方案，用于治疗影响骨骼健康和血管功能的罕见疾病。我们是PPi-腺苷途径的专家，其中ENPP1酶生成无机焦磷酸盐（PPi），用于调节矿化，和腺苷，用于控制血管内膜增生（血管内平滑肌细胞的过度增长）。该途径的紊乱会影响这些分子的水平，导致严重的肌骨骼，心血管和神经病症，包括ENPP1缺乏，ABCC6缺乏，钙化性坏死和后纵韧带骨化（OPLL）。
Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these molecules. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases.
我们的首席候选药物INZ-701是一种ENPP1 Fc融合蛋白酶替代疗法(ERT)，旨在增加PPi和腺苷，从而有可能治疗由这些分子缺乏引起的多种疾病。目前，它正处于ENPP1缺陷、ABCC6缺陷和钙磷病的临床开发阶段。通过靶向PPi-腺苷途径，INZ-701旨在纠正病理性矿化和intimal增殖，从而应对这些毁灭性疾病中的重要发病率和死亡率问题。
For more information, please visit or follow Inozyme on LinkedIn, X, and Facebook.
如需更多信息，请访问或关注Inozyme的LinkedIn、X和Facebook页面。
Contacts
联系方式
Investors:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Corporate Communications
(617) 461-2442
stefan.riley@inozyme.com
投资者:
inozyme pharma
IR和企业通讯高级董事Stefan Riley
(617) 461-2442
stefan.riley@inozyme.com
Media:
Biongage Communications
Todd Cooper
(617) 840-1637
todd@biongage.com
媒体:
Biongage通信-半导体
Todd Cooper
(617) 840-1637
todd@biongage.com
